Kota Denpasar

Researchers are evaluating the immune response and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine (PCV13) in healthy infants in Indonesia. The study aims to show that the immune response from the new PCV13-DT/TT vaccine is not worse than that from PCV13 when given alongside Hexavalent vaccines at specific infant ages. This phase 3 clinical trial includes infants vaccinated at 2, 4, and between 12 to 15 months of age to assess these outcomes. About 500 infants aged 6 to 8 weeks will be randomly assigned to two groups: one receiving the study PCV13 vaccine and the other receiving Pfizer's Prevenar13 vaccine. Both groups will receive their respective vaccines at 2, 4, and 12 to 15 months of age. Meanwhile, the Hexavalent vaccine will be administered at 2, 3, and 4 months of age. This schedule follows WHO recommendations for infant vaccination. Participants will be monitored through scheduled visits, vaccination plans, and laboratory tests to assess immune responses and safety. The main outcome measured is the percentage of infants with protective antibody levels 30 days after the booster dose. Researchers will also track any side effects and overall safety during the study. Participation will include informed consent from parents or guardians and follow-up throughout the vaccination period.

Researchers are evaluating three training methods to see which best improves muscle structure and helps prevent Patellofemoral Pain Syndrome and ACL injuries in sportsmen aged 15 to 35 who play sports like martial arts, basketball, futsal, and soccer at least twice a week. The study compares low-load blood flow restriction training (LL-BFRt), a sham version of this training, and high-load eccentric training (HL-Et). Participants have no prior history of these knee injuries or severe sprains and will be randomly assigned to one of the three groups. In the LL-BFRt group, participants perform eccentric exercises such as stairs, single leg squats, and single leg deadlifts at 30% of their maximum repetition with 70% artery occlusion pressure applied by cuffs. The sham LL-BFRt group follows the same exercises at 30% maximum repetition but with only 10% artery occlusion pressure. The HL-Et group performs the same eccentric exercises at a higher intensity of 70% maximum repetitions without blood flow restriction. Physical therapists supervise all exercises. Participants will be assessed over 8 weeks for changes in muscle size, fiber angle of a thigh muscle (vastus medial obliques), and patella position to measure muscle morphology improvements. Researchers will compare the effectiveness of the three training types in improving muscle features and preventing knee injuries. The study involves consenting adults and continues until the conclusion of the trial to collect all necessary data.

Emergence agitation is a common problem in children recovering from general anesthesia, especially with sevoflurane. This condition involves confusion, restlessness, and distress, which can make recovery difficult for both children and caregivers. Researchers are studying whether giving a lollipop after surgery can help reduce these symptoms in pediatric patients aged 2 to 6 years undergoing surgery at RS Ngoerah. In this randomized controlled trial, children will be randomly assigned to receive either a lollipop during the immediate recovery period after surgery or standard postoperative care without a lollipop. The study will compare these two groups to see if the lollipop reduces the frequency and severity of emergence agitation. Outcome assessors will use standardized scales to measure agitation and observe recovery time, comfort, and any side effects. Participants will be monitored closely after surgery, with agitation levels recorded using a validated scoring system during the first hour after anesthesia. Additional observations may include how long agitation lasts and whether rescue medications are needed. The study aims to find a simple, safe, and cost-effective way to improve recovery in young children after general anesthesia.

Researchers are evaluating the effectiveness of a specific nerve block technique called Modified Thoracoabdominal Nerve Block Perichondrial Approach (M-TAPA) to manage postoperative pain in patients undergoing laparoscopic cholecystectomy. The study aims to compare this nerve block method to the standard postoperative use of intravenous opioids, focusing on reducing pain and opioid consumption within 24 hours after surgery. The trial involves adult patients aged 18 to 65 years with certain health criteria. Participants are divided into two groups: one group receives the M-TAPA nerve block administered by an anesthesiologist after surgery, involving an ultrasound-guided injection of a local anesthetic on both sides of the upper abdomen. The other group receives intravenous opioids through a patient-controlled analgesia (PCA) device without the nerve block. Both groups undergo general anesthesia and the same laparoscopic surgery procedure. Patients are monitored closely for any side effects or complications during and after the surgery. During the study, patients are observed in the recovery room and hospital ward, with pain levels measured using a Numeric Rating Scale at various times up to 24 hours post-surgery. Researchers also record total opioid use from the PCA machine and assess recovery quality before and after surgery. Vital signs and potential side effects like hypotension or bradycardia are carefully monitored throughout. The study lasts for 24 hours following the operation to evaluate pain relief effectiveness and safety.

Researchers are evaluating the effectiveness of secretome injections compared to intradermal platelet-rich plasma (PRP) injections in patients with androgenetic alopecia. This experimental study uses a randomized controlled clinical design to assess hair density and the ratio of terminal-to-vellus hair in patients aged 25 to 59 years with specific clinical grades of alopecia. The research takes place at Prof. Dr. I.G.N.G. Ngoerah General Hospital. Participants receive either UC-MSC secretome injections or intradermal PRP injections into the scalp at the alopecia sites. Injections are spaced 1 cm apart and administered every 2 weeks for a total of 8 weeks. Both treatments are given intradermally and involve biological substances prepared specifically for this study. During the study, hair density and the terminal-to-vellus hair ratio are measured at baseline, 8 weeks post-treatment, and during follow-up visits at 3, 6, and 9 months using trichoscopy or dermoscopy. Participants are monitored closely for changes in hair growth, and safety is assessed throughout the study period. The total duration includes the treatment phase and follow-up assessments to evaluate lasting effects.